GANX Company Profile and Key Details
Gain Therapeutics, Inc.
GANX Stock Price Chart
Stock Price Today
Gain Therapeutics, Inc. (GANX) stock declined over -3.80%, trading at $2.28 on NASDAQ, down from the previous close of $2.37. The stock opened at $2.44, fluctuating between $2.22 and $2.47 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Company Information
| Employees | 29 |
| Beta | 0.34 |
| Sales or Revenue | $55.18K |
| 5Y Sales Change% | 0.206% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Gain Therapeutics, Inc. (NASDAQ: GANX) stock price is $2.28 in the last trading session. During the trading session, GANX stock reached the peak price of $2.47 while $2.22 was the lowest point it dropped to. The percentage change in GANX stock occurred in the recent session was -3.8% while the dollar amount for the price change in GANX stock was -$0.09.
The NASDAQ listed GANX is part of Biotechnology industry that operates in the broader Healthcare sector. Gain Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Natalia Perez-Carmona Ph.D.
Head of Biology
Dr. Joanne Taylor Ph.D.
Senior Vice President of Research & Scientific Advisor
Dr. Terenzio Ignoni Pharm.D.
Senior Vice President of Technical Operations
Dr. Xavier Barril Ph.D.
Chief Technology Officer
Dr. Manolo Bellotto Ph.D.
GM & Chief Strategy Officer
Dr. Ana Maria Garcia-Collazo Ph.D.
Head of Research
Dr. Khalid Islam Ph.D.
Founder & Chairman
Mr. Salvatore Calabrese
Chief Financial Officer & Corporation Sec.
Mr. Gianluca Fuggetta
Principal Accounting Officer & Senior Director of Corporation Reporting
Mr. Matthias Alder LIC. IUR., LL.M.
Pres, Chief Executive Officer & Director
Mr. C. Evan Ballantyne
Chief Financial Officer & Sec.
GANX's closing price is 156.18% higher than its 52-week low of $0.89 where as its distance from 52-week high of $5.33 is -57.22%.
Number of GANX employees currently stands at 29.
Official Website of GANX is: https://www.gaintherapeutics.com
GANX could be contacted at phone 301 500 1556 and can also be accessed through its website. GANX operates from 4800 Montgomery Lane, Bethesda, MD 20814, United States.
GANX stock volume for the day was 272.61K shares. The average number of GANX shares traded daily for last 3 months was 255.54K.
The market value of GANX currently stands at $60.48M with its latest stock price at $2.28 and 26.53M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com